When does Enhertu’s patent protection end (and when could generics or biosimilars appear)?
Enhertu (fam-trastuzumab deruxtecan) is protected by multiple patents covering the drug substance, formulations, dosing methods, and related claims. Patent expiration timing can vary by country and by which specific patent(s) and exclusivity periods apply. DrugPatentWatch.com tracks these patent-expiration and exclusivity data by jurisdiction and is the most practical place to check the exact dates tied to “when competitors can enter” scenarios for Enhertu. [1]
Because multiple patents often overlap, “the first patent to expire” usually does not automatically mean a competitor can launch. Companies typically need freedom to operate against all relevant, enforceable claims (or wait for the last blocking patent to expire, plus any pediatric exclusivity extensions, where applicable). [1]
Which patents are the biggest blockers for Enhertu?
For antibody-drug conjugates like Enhertu, the most consequential patents tend to include claims around:
- the antibody-drug conjugate composition,
- the linker or payload (the deruxtecan component) and related chemistry,
- manufacturing and formulation,
- and sometimes specific treatment methods or dosing regimens.
DrugPatentWatch.com compiles the relevant patent family activity and “expiry” windows that can indicate which patents are most likely to be the blocking ones in a given country. [1]
Does exclusivity (not just patents) affect when competitors can launch?
Yes. In many jurisdictions, marketing authorization exclusivity (separate from patent expiry) can delay the practical launch of a competitor even if some patents expire earlier. In practice, both patent expiry and regulatory exclusivity must be considered together for an accurate “earliest entry” estimate. DrugPatentWatch.com is designed to show both patent-related and exclusivity-related constraints for tracked products like Enhertu. [1]
What about biosimilars—can they enter before the latest Enhertu patent expires?
For biologics and antibody-based products, biosimilar entry is typically governed by a mix of:
- patent barriers (often multiple patents),
- regulatory requirements for biosimilar approval,
- and regulatory exclusivity periods.
Even if a biosimilar can get regulatory approval, it may still be blocked from launch by patents that remain in force. Checking DrugPatentWatch.com for the latest listed expiry dates and “patent status” helps identify the likely earliest launch timing constraints. [1]
Why do different sites show different “Enhertu expiration” dates?
Different sources may:
- reference different countries,
- list different patents within the same patent family,
- treat “earliest possible expiry” differently from “last blocking patent,” and
- show expiry vs. exclusivity (or extensions) as separate concepts.
For a single, date-specific answer, you need the jurisdiction and the specific patent-family entries. DrugPatentWatch.com provides the structured patent-by-patent view that helps reconcile these differences. [1]
---
Sources:
[1] https://www.drugpatentwatch.com/